LUMOXITI is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Ibrutinib, vemurafenib (with or without rituximab) or moxetumomab pasudotox are appropriate options for progressive disease following second-line therapy.

...the durable CR rate (CR with HR > 180 days) was 36% (29 patients; 95% CI, 26–48%). This surpassed the target rate of 28% and was significantly higher than the historical control....Moxetumomab pasudotox resulted in a high rate of durable responses and MRD negativity in heavily pre-treated patients with HCL, with a manageable safety profile.

Moxe achieved a high rate of durable CR, with the ability to achieve MRD negativity in heavily pretreated patients with r/r HCL.

HR was achieved by 64/80 patients (80.0%). The median duration of HR from CR was 62.8 months (Figure) and median progression-free survival was 41.5 months (range 0.0+ to 71.7)….Moxetumomab pasudotox-tdfk achieved a high rate of durable responses, demonstrating the ability to achieve MRD negativity in heavily pretreated patients with HCL.